RE: Expectations19 Mar 2025 14:19
its easy to get distracted by the weak share price, nut looking thought he numbers in more detail really shows the momentum building.
cash balance post disposal stands at a staggering $1.44b v current market cap £2.1b
hey, but we are a hedge fund, don't worry about trivia like that ..lol
------------------------------------------------------------------------------------------------
global commercial progress and delivery of sustainable growth
· fruzaqla® (fru*****inib) ex-china in-market sales1 of $290.6 million in 2024 by takeda, sustaining momentum in its first full year driven by rapid us patient uptake, and eu and japan launches, triggering a sales milestone from takeda2. total oncology products in-market sales up 134% to $501.0 million.
· consolidated revenue from oncology products of $271.5 million, up 65%.
· net income of $37.7 million was achieved in 2024, with a cash balance of $836.1 million as of december 31, 2024, achieving financial self-reliance ahead of schedule.
· agreed partial disposal of equity in shpl3 joint venture for $608 million.